SONIDEGIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H26F3N3O3
Molecular Weight	485.4981
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CN(C[C@@H](C)O1)C2=CC=C(NC(=O)C3=CC=CC(C4=CC=C(OC(F)(F)F)C=C4)=C3C)C=N2

InChI

InChIKey=VZZJRYRQSPEMTK-CALCHBBNSA-N

InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB09143

Sonidegib, also known as LDE225 and marketed as Odomzo, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was approved by the FDA for treating basal cell carcinoma in July 2015 and is awaiting approval in the EU. The hedgehog pathway is involved in many human cancers. Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning. As a result, tumours that depend on the hedgehog pathway are unable to grow. Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Smoothened homolog 20 Target ID: Q99835 Gene ID: 6608.0 Gene Symbol: SMO Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900187	Antagonist 2778		2.5 nM [IC50]
Smoothened homolog 20 Target ID: CHEMBL5971 Sources: https://www.drugbank.ca/drugs/DB09143	Antagonist 2778		2.5 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Basal cell carcinoma 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf	Primary		Approved 8429	ODOMZO Approved Use ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Launch Date 2015

C_max

Value	Dose	Co-administered	Analyte	Population
1030 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SONIDEGIB unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
22 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SONIDEGIB unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% EXPERIMENT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422158/			SONIDEGIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3000 mg 1 times / day multiple, oral Highest studied dose Dose: 3000 mg, 1 times / day Route: oral Route: multiple Dose: 3000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26898300 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf	unhealthy n = 10 Health Status: unhealthy Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/26898300 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf	Other AEs: Creatine kinase increased, Rhabdomyolysis... Other AEs: Creatine kinase increased (grade 3-4, 1 patient) Rhabdomyolysis (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26898300 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf
800 mg 1 times / day steady, oral MTD Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104	unhealthy n = 150 Health Status: unhealthy Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104	DLT: Creatine kinase increased... Disc. AE: Muscle spasms, Alopecia... Dose limiting toxicities: Creatine kinase increased (2%) AEs leading to discontinuation/dose reduction: Muscle spasms (9%) Alopecia (6%) Dysgeusia (5%) Weight decreased (5%) Fatigue (2%) Asthenia (1%) Nausea (4%) Decreased appetite (5%) Arthralgia (1%) Dysphagia (1%) General physical health deterioration (1%) Ageusia (2%) Dehydration (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104
800 mg 1 times / day steady, oral MTD Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 105	unhealthy n = 150 Health Status: unhealthy Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 105	Disc. AE: Anemia, Constipation... AEs leading to discontinuation/dose reduction: Anemia (1%) Constipation (1%) Hypertension (1%) Hypogeusia (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 105
800 mg 1 times / day steady, oral MTD Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106	unhealthy n = 150 Health Status: unhealthy Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106	Disc. AE: Diarrhea, Gastroenteritis viral... AEs leading to discontinuation/dose reduction: Diarrhea (5%) Gastroenteritis viral (1%) Rhabdomyolysis (1%) Alanine aminotransferase increased (2%) Aspartate aminotransferase increased (2%) Dizziness (1%) Myalgia (3%) Muscular weakness (1%) Blood uric acid increased (1%) Vomiting (7%) Dyspnea (1%) Myoglobin blood increased (1%) Hypogeusia (1%) Amylase increased (1%) Malaise (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Disc. AE: Amylase increased... AEs leading to discontinuation/dose reduction: Amylase increased (grade 3-4, 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Disc. AE: Alanine aminotransferase increased, Aspartate aminotransferase increased... AEs leading to discontinuation/dose reduction: Alanine aminotransferase increased (grade 3-4, 4%) Aspartate aminotransferase increased (all grades, 19%) Asthenia (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	Disc. AE: Muscle spasms, Myalgia... Other AEs: Muscle spasms, Musculoskeletal pain... AEs leading to discontinuation/dose reduction: Muscle spasms (grade 3, 3%) Myalgia (all grades, 19%) Alopecia (all grades, 53%) Diarrhea (grade 3, 1%) Weight decreased (grade 3, 3%) Decreased appetite (grade 3, 1%) Other AEs: Muscle spasms (all grades, 54%) Musculoskeletal pain (all grades, 32%) Musculoskeletal pain (grade 3, 1%) Pruritus (all grades, 10%) Headache (all grades, 15%) Headache (grade 3, 1%) Fatigue (all grades, 41%) Pain (all grades, 14%) Pain (grade 3, 1%) Nausea (all grades, 39%) Diarrhea (all grades, 32%) Abdominal pain (all grades, 18%) Vomiting (all grades, 11%) Weight decreased (all grades, 30%) Decreased appetite (all grades, 23%) Increased serum creatinine (all grades, 92%) Creatine kinase increased (all grades, 61%) Hyperglycemia (all grades, 51%) Hyperglycemia (grade 3-4, 4%) Lipase increased (all grades, 43%) Alanine aminotransferase increased (all grades, 19%) Aspartate aminotransferase increased (grade 3-4, 4%) Amylase increased (all grades, 16%) Anemia (all grades, 32%) Lymphopenia (all grades, 28%) Lymphopenia (grade 3-4, 3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Disc. AE: Dysgeusia, Fatigue... AEs leading to discontinuation/dose reduction: Dysgeusia (all grades, 46%) Fatigue (grade 3, 4%) Nausea (grade 3, 1%) Vomiting (grade 3, 1%) Creatine kinase increased (grade 3-4, 8%) Lipase increased (grade 3-4, 13%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104	Disc. AE: Arthralgia, Dysphagia... AEs leading to discontinuation/dose reduction: Arthralgia (1 patient) Dysphagia (1 patient) General physical health deterioration (1 patient) Abdominal pain upper (1 patient) Agitation (1 patient) Depression (1 patient) Dry mouth (1 patient) Lumbar vertebral fracture (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 104
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106	Disc. AE: Rhabdomyolysis, Dizziness... AEs leading to discontinuation/dose reduction: Rhabdomyolysis (1%) Dizziness (1%) Pneumonia (1%) Muscular weakness (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 106
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 107	unhealthy n = 79 Health Status: unhealthy Condition: locally advanced BCC Population Size: 79 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 107	Disc. AE: Blood uric acid increased, Angina pectoris... AEs leading to discontinuation/dose reduction: Blood uric acid increased (1%) Angina pectoris (1%) Anorectal infection (1%) Back pain (1%) Bile duct stone (1%) Cough (1%) Disturbance in attention (1%) Femoral neck fracture (1%) Gastric ulcer (1%) Influenza (1%) Sleep disorder (1%) Spinal compression fracture (1%) Upper respiratory tract infection (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf Page: 107

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 647 CYP1A2 1524 CYP2C8 911 CYP2C19 1478 CYP2B6 810 P-gp 1461 MRP2 383 BCRP 699 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OCT1 512 CYP3A 214	P-gp 1537 MRP2 205 BCRP 561

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
CYP3A 298	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
MRP2 475	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	yes [IC50 1.5 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -	yes [Ki 0.045 uM]	unknown (co-administration study) Comment: study to assess the effects of sonidegib on the PK of a CYP2B6 and a CYP2C9 probe substrate is ongoing Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -	yes [Ki 1.7 uM]	unknown (co-administration study) Comment: study to assess the effects of sonidegib on the PK of a CYP2B6 and a CYP2C9 probe substrate is ongoing Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -	major	yes (co-administration study) Comment: Sonidegib is metabolized by CYP3A4 to several inactive metabolites. Ketoconazole increased sonidegib AUC0-10d by 2.2-fold and rifampicin decreased sonidegib AUC0-10d by 72% following a single 800 mg dose in healthy subjects. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=7 Page: -
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
MRP2 205	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf#page=28 Page: -	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000PharmR.pdf#page=16 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:90863	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90863
ChemicalBook	CB52515129	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52515129
MolPort	MolPort-009-194-121	https://www.molport.com/shop/molecule-link/MolPort-009-194-121
MolPort	MolPort-047-116-775	https://www.molport.com/shop/molecule-link/MolPort-047-116-775
Selleck Chemicals	LDE225(NVP-LDE225)	http://www.selleckchem.com/products/LDE225(NVP-LDE225).html
ZINC	ZINC000068202099	http://zinc15.docking.org/substances/ZINC000068202099
eMolecules	32278194	https://www.emolecules.com/cgi-bin/more?vid=32278194

PubMed

Title	Date	PubMed
		252160304

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dose: 200 mg orally once daily taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

Route of Administration: Oral

In Vitro Use Guide

Sonidegib inhibits TM3 luciferized cell line with 0.6 nM and 8 nM, at the presence of 1 nM and 25 nM Hh agonist Ag1.5, respectively.

Name

Type

Language

SONIDEGIB

Official Name

English

(1,1'-BIPHENYL)-3-CARBOXAMIDE, N-(6-((2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL)-3-PYRIDINYL)-2-METHYL-4'-(TRIFLUOROMETHOXY)-, REL-

Common Name

English

LDE 225

Code

English

sonidegib [INN]

Common Name

English

NVP-LDE225

Code

English

SONIDEGIB [USAN]

Common Name

English

Sonidegib [WHO-DD]

Common Name

English

NVP-LDE 225

Code

English

N-(6-((2R,6S)-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDIN-3-YL)-2-METHYL-4'-(TRIFLUOROMETHOXY)BIPHENYL-3-CARBOXAMIDE

Systematic Name

English

N-(6-((CIS-2,6-DIMETHYLMORPHOLIN-4-YL)-3-PYRIDYL)-2-METHYL-3-(4-(TRIFLUOROMETHOXY)PHENYL)BENZAMIDE

Common Name

English

LDE-225

Code

English

LDE225

Code

English

NVP-LDE-225

Code

English

ERISMODEGIB

Common Name

English

SONIDEGIB [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2189